“The Case for Quality” report

Aug 31, 2018 | Quality

New publication from USP, UNITAID and the Government of Ethiopia

Poor-quality medicines undermine the treatment of some of the world’s most pressing diseases, such as tuberculosis, malaria, and HIV/AIDS, and potentially contribute to anti-microbial resistance. The risk is greatest in low- and middle-income countries, where an estimated 10 percent of medicines are substandard or falsified.

Following the highly successful “Incentivising Investments in Quality Medicines” event at the World Health Assembly, USP and partners in the #MedsWeCanTrust Campaign have released a report into the learnings from the event.  As a #MedsWeCanTrust partner, we are happy to share the report: The Case for Quality.